Black Stool: Complete Guide to Melena, Causes & When It Is a Medical Emergency

Black stool is one of the few gastrointestinal symptoms that can represent a true medical emergency. The medical term melena refers specifically to black, tarry, foul-smelling stool produced when blood from the upper gastrointestinal tract (esophagus, stomach, duodenum, or proximal small intestine) is partially digested as it transits through the gut. Iron in the blood is oxidized by gastric acid and bacterial action, producing the characteristic dark color and tarry consistency. The presence of melena typically indicates 50-100 mL or more of upper GI bleeding — enough to warrant prompt medical evaluation in all cases.

However, not all black stool is melena. Several benign causes mimic the appearance: iron supplementation, bismuth-containing medications (Pepto-Bismol), and certain dark-colored foods (blueberries, black licorice, dark leafy greens in excess). The diagnostic challenge — and what this guide addresses — is distinguishing potentially life-threatening melena from benign mimickers, understanding when to seek emergency care, and knowing the underlying causes when bleeding is the explanation.

This guide walks through the biology of melena, the full differential diagnosis for black stool, when to seek emergency care versus when home observation is appropriate, structured workup and emergency-department evaluation, the major upper GI bleeding sources and their treatment, benign mimickers and how to confirm them, recovery and follow-up considerations, and how black stool relates to ongoing gut-health concerns (particularly the Upper GI/Reflux pattern). By the end you will have a clear decision framework for any episode of black stool.

Critical safety note: If you have black tarry stool combined with any of dizziness, lightheadedness on standing, weakness, rapid heart rate, chest pain, abdominal pain, vomiting blood or coffee-ground material, recent use of NSAIDs or anticoagulants, or known history of peptic ulcer, esophageal varices, or upper GI cancer — call emergency services or go to the nearest emergency department immediately. Do not wait. Black stool in these settings is a medical emergency that can deteriorate rapidly.

The Biology: What Makes Stool Black

True melena: oxidized blood

When blood enters the upper GI tract — from a bleeding esophageal varix, stomach ulcer, duodenal ulcer, or proximal small bowel lesion — it begins a chemical transformation. Gastric acid (HCl) interacts with the iron in hemoglobin, oxidizing it. Bacterial enzymes in the small intestine and proximal colon further break down the blood components. By the time the stool reaches the rectum, the oxidized iron and digested blood components give the stool a distinctive jet-black color, a sticky tarry consistency, and an unmistakable foul, "old-blood" odor that is different from the smell of normal stool.

Several features distinguish true melena from other forms of black stool:

• Color: jet black, sometimes called "tarry" or "asphalt-like"
• Consistency: sticky, tar-like, often loose or semi-formed
• Odor: extremely foul, distinctive, persistent
• Quantity: enough volume to noticeably stain toilet water dark
• Associated symptoms: weakness, dizziness, fatigue, nausea, abdominal discomfort, possibly vomiting blood

Approximately 50-100 mL of upper GI blood loss is required to produce visible melena. Bleeding from the lower GI tract (colon, rectum) typically does not produce melena because the blood transits too quickly to undergo full oxidation — it appears as red or maroon blood (hematochezia) instead.

Benign black stool mimickers

Several causes produce black stool without GI bleeding:

Iron supplements: Oral iron salts (ferrous sulfate, ferrous fumarate, ferrous gluconate) produce darkening of stool through unabsorbed iron oxidation. This is one of the most common causes of "scary" black stool that turns out to be benign. The stool is dark but typically does not have the distinctive tar consistency or foul odor of true melena. Stool can be greenish-black, dark brown-black, or jet black depending on the iron dose and individual GI transit.

Bismuth subsalicylate (Pepto-Bismol, Kaopectate): Bismuth interacts with sulfur in saliva and the GI tract to produce bismuth sulfide, a black-colored compound. Both stool and tongue can appear black during bismuth use. This is harmless and resolves within 1-3 days of discontinuing bismuth.

Activated charcoal: Produces dramatic black stool that resolves with discontinuation.

Dietary causes: Black licorice (real, not just-flavored), blueberries in large quantity, dark leafy greens (kale, spinach) in unusual excess, beets and beet-derived products, food coloring (especially black food dyes used in seasonal foods), and chocolate or dark chocolate-heavy desserts can produce darker-than-normal stool. These rarely produce truly jet-black stool but can dim the color enough to cause concern.

Medications: Some medications other than iron and bismuth can darken stool — certain inhalers (theophylline), some antidepressants in some patients, and rarely others. Review medication list when investigating black stool.

The Emergency Decision Framework

Call emergency services / go to ED immediately

Any of the following with black stool requires emergency care:

• Vomiting blood (bright red or coffee-ground appearance)
• Dizziness, lightheadedness, fainting, or near-fainting
• Rapid heart rate at rest or with standing
• Pale or clammy skin
• Weakness preventing normal activity
• Chest pain or shortness of breath
• Severe abdominal pain
• Confusion or altered mental state
• Known history of esophageal varices, peptic ulcer disease with prior bleeding, or upper GI cancer
• Recent significant NSAID use (ibuprofen, naproxen, aspirin) plus black stool
• Current anticoagulant therapy (warfarin, apixaban, rivaroxaban, dabigatran) plus black stool
• Significant alcohol use history with new black stool

Urgent evaluation (within 24 hours)

• Black stool without obvious benign cause (not on iron, bismuth, or dark-food intake)
• Black stool with abdominal pain that is not severe
• Black stool with mild fatigue or pallor
• Persistent black stool over 2+ bowel movements without explanation
• New onset over age 50 without clear benign cause

Routine evaluation (within days)

• Black stool clearly correlated with iron supplement use (consider reduced dose or different form)
• Black stool with recent bismuth use that has resolved on stopping
• Dietary-correlated dark stool that resolves on stopping the food
• Mild dark stool without other features in someone with known benign cause

Observation appropriate (no urgent evaluation needed)

• Recently started iron supplement, stool darker than usual, otherwise well, no alarm features
• Currently using bismuth subsalicylate (Pepto-Bismol or similar), stool black, otherwise well
• Heavy blueberry, black licorice, or dark food consumption with darkening that resolves

The critical question

The single most important diagnostic question: Are you currently taking iron supplements, bismuth-containing medication, or have you had unusual dark-food intake recently? If the answer is "yes" and you have no alarm symptoms, the cause is almost certainly the benign mimicker. If the answer is "no" and the stool is truly tarry and foul, melena is presumed until proven otherwise.

The "wipe test" can sometimes help: smear a small amount of stool on white paper. Iron-related darkening typically produces a greenish-brown or dark-brown smear; true melena produces a jet-black, sticky smear. This is a rough heuristic, not diagnostic.

Causes of True Melena: The Major Upper GI Bleeding Sources

Peptic ulcer disease (PUD)

Peptic ulcers — including gastric ulcers (in the stomach) and duodenal ulcers (in the first part of the small intestine) — are the most common cause of upper GI bleeding requiring hospitalization. Ulcers develop from imbalance between mucosal defense and acid/pepsin attack. The two major contributors are:

• Helicobacter pylori infection: A spiral-shaped bacterium that infects the gastric mucosa and produces inflammation and ulceration in susceptible individuals. Worldwide prevalence varies from 30-80% depending on population. Eradication with combination antibiotics is curative.
• NSAID-induced ulceration: Ibuprofen, naproxen, aspirin, ketorolac, and other non-steroidal anti-inflammatory drugs damage gastric mucosa through prostaglandin inhibition. Chronic use, high doses, advanced age, history of prior ulcer, and concurrent corticosteroid or anticoagulant use all multiply risk.

Less common contributors: severe physiological stress (ICU patients), Zollinger-Ellison syndrome (gastrin-secreting tumor), Crohn's disease in the upper GI tract.

Classic presentation: epigastric pain, often relieved or worsened by meals (duodenal ulcers classically improve with food; gastric ulcers often worsen with food), early satiety, occasional nausea. Bleeding can present as melena, hematemesis (vomiting blood), coffee-ground emesis, or hemodynamic instability without obvious bleeding.

Diagnosis: upper endoscopy (EGD). Treatment: proton pump inhibitors (PPI), H. pylori eradication if positive, NSAID cessation, sometimes endoscopic intervention for active bleeding.

Esophageal and gastric varices

Varices are dilated, abnormal veins in the esophagus or stomach that develop in patients with portal hypertension — usually from cirrhosis but also from portal vein thrombosis, schistosomiasis, or other causes. Variceal bleeding is among the most life-threatening forms of GI bleeding, with mortality of 15-25% per bleeding episode. Risk factors: known cirrhosis, alcohol use disorder, chronic hepatitis B or C, hemochromatosis, autoimmune liver disease.

Presentation: often massive bleeding — large-volume melena, vomiting bright red blood, or both. Hemodynamic instability common. Patients may have known liver disease with stigmata (spider angiomata, palmar erythema, jaundice, ascites).

Diagnosis: emergency endoscopy. Treatment: emergency band ligation or sclerotherapy, intravenous octreotide, broad-spectrum antibiotics (variceal bleeding has high secondary infection risk), TIPS (transjugular intrahepatic portosystemic shunt) for refractory cases, eventual liver transplant evaluation for severe portal hypertension.

Mallory-Weiss tear

A longitudinal tear in the lower esophageal mucosa from forceful vomiting or retching. Classically presents with hematemesis following a forceful vomiting episode (alcohol-related vomiting, hyperemesis gravidarum, severe gastroenteritis). Most resolve spontaneously; significant bleeding may require endoscopic intervention.

Gastritis and erosive gastritis

Inflammation of the gastric mucosa from various causes: NSAIDs, alcohol, severe stress (ICU patients), H. pylori, autoimmune (pernicious anemia), or post-radiation. Diffuse erosions can produce significant bleeding even without a discrete ulcer. Treatment: address the cause, PPI, supportive care.

Esophagitis

Severe esophageal inflammation can bleed, producing melena. Causes: severe GERD with erosive esophagitis, infectious esophagitis (Candida, herpes, CMV in immunocompromised patients), pill esophagitis (doxycycline, bisphosphonates, potassium chloride pills lodging in esophagus), eosinophilic esophagitis. Treatment: cause-specific.

Vascular malformations

Angiodysplasias (also called arteriovenous malformations or AVMs) are abnormal dilated blood vessels in the GI mucosa that can bleed. More common in older adults, those with aortic stenosis, chronic kidney disease, or hereditary hemorrhagic telangiectasia. Often produce recurrent bleeding episodes. Diagnosis: endoscopy or capsule endoscopy for small bowel lesions. Treatment: endoscopic cauterization, argon plasma coagulation, or surgery for refractory cases.

Upper GI malignancy

Gastric cancer, esophageal cancer, ampullary cancer, and small bowel cancers can present with chronic occult bleeding (positive fecal occult blood) progressing to melena. Risk factors vary by cancer type. Concerning features: progressive weight loss, dysphagia (esophageal), early satiety, persistent nausea, family history of GI cancer. Diagnosis: endoscopy with biopsy, imaging staging. Treatment: surgery, chemotherapy, radiation per cancer type.

Dieulafoy's lesion

A large, tortuous arteriole running close to the mucosal surface, usually in the proximal stomach. Can produce dramatic, sometimes life-threatening bleeding. Diagnosis: endoscopy. Treatment: endoscopic intervention.

Aortoenteric fistula (rare but lethal)

An abnormal connection between the aorta (usually after prior aortic surgery with graft) and the duodenum or small bowel. Can produce massive sudden bleeding. Suspect in patients with prior abdominal aortic aneurysm repair who present with melena. Surgical emergency.

Workup for Black Stool: From Bedside to Endoscopy

Emergency department evaluation

For black stool with any alarm features:

• Vital signs: Heart rate, blood pressure (lying and standing for orthostatic changes), respiratory rate, oxygen saturation
• History: Medications (NSAIDs, anticoagulants, antiplatelets, iron, bismuth), alcohol use, prior GI bleeding, dietary review
• Physical exam: Abdominal tenderness, masses, hepatosplenomegaly, signs of liver disease (jaundice, spider angiomata, palmar erythema), digital rectal exam to confirm melena
• Stool inspection: Confirm melena character (tarry, foul, jet black) vs. other dark stool
• Bedside testing: Hemoccult or guaiac test for occult blood; nasogastric tube aspiration in some cases to confirm upper GI source

Initial laboratory testing

• Complete blood count (CBC): Hemoglobin and hematocrit; baseline may underestimate acute blood loss until fluid shifts occur (often within hours to a day)
• BUN to creatinine ratio: Elevated ratio (greater than 30:1) suggests upper GI bleeding (digested blood produces urea absorbed in the small intestine)
• INR or PT, PTT: Coagulation status, particularly important if on anticoagulants or liver disease
• Comprehensive metabolic panel: Renal and liver function
• Type and screen: Blood type for potential transfusion
• Lactate: Marker of tissue perfusion in significant bleeding

Endoscopy (EGD)

Upper endoscopy is the diagnostic and therapeutic procedure for melena. Performed in the next 12-24 hours for hemodynamically stable patients, more urgently for unstable patients. The procedure allows:

• Direct visualization of esophagus, stomach, and duodenum
• Identification of bleeding source
• Endoscopic intervention: cautery, hemoclips, band ligation, sclerotherapy
• Biopsy of suspicious lesions for malignancy or H. pylori
• Often single procedure handles both diagnosis and treatment

If EGD is non-diagnostic

If upper endoscopy does not identify a source, the next steps depend on continued bleeding or stability:

• Push enteroscopy or balloon-assisted enteroscopy: Further visualization of the small bowel
• Video capsule endoscopy: A swallowed camera captures images throughout small bowel
• CT angiography: Identifies actively bleeding vessels
• Tagged red blood cell scan: Detects slower bleeding
• Colonoscopy: Confirms no proximal colonic source mimicking melena
• Repeat EGD: Some lesions are missed on first endoscopy

Supportive treatment during workup

• Intravenous fluid resuscitation for hemodynamic instability
• Blood transfusion if hemoglobin below 7-8 g/dL or symptomatic anemia
• Intravenous proton pump inhibitor (esomeprazole or pantoprazole drip) — reduces ongoing bleeding from acid-peptic sources
• Octreotide infusion if variceal bleeding suspected
• Antibiotics for suspected variceal bleeding
• Reversal of anticoagulation as appropriate
• NPO (nothing by mouth) until source identified and stabilized

Confirming Benign Mimickers

When black stool clearly correlates with a benign cause and there are no alarm features, the diagnosis can often be confirmed without invasive workup.

Iron supplements

If you recently started oral iron and developed darker stool:

• Color is typically greenish-black or dark brown-black, not jet black
• Consistency is normal, not tarry
• No foul smell (the smell is normal-stool, not blood-decomposition)
• You feel well; no anemia symptoms, dizziness, or weakness

If these features fit, observation is reasonable. If concerned, a fecal occult blood test (FIT or guaiac) can confirm absence of blood. If you have anemia being treated with iron and develop true melena features, do not assume the iron is the cause — the underlying anemia may itself be from chronic GI blood loss that has now become overt.

Bismuth subsalicylate

• Currently using Pepto-Bismol, Kaopectate, or other bismuth-containing product
• Tongue may also appear black or darkened
• Stool returns to normal within 1-3 days of discontinuation
• No alarm symptoms

Dietary causes

• Recent unusual intake of dark foods (black licorice, blueberries, black-dyed foods, beets)
• Stool darkening resolves within 24-48 hours after returning to typical diet
• No tarry consistency or foul odor
• No alarm symptoms

When to test despite suspected benign cause

Even when a benign cause seems likely, fecal occult blood testing (FIT — fecal immunochemical test) is reasonable if:

• You are over 50 and have not had recent colorectal cancer screening
• You have family history of GI cancer
• You have unexplained anemia
• You have any of the alarm features in a milder form
• The dark stool persists beyond expected duration of the suspected benign cause

Common Conditions in Detail

Helicobacter pylori infection

H. pylori is one of the most common chronic bacterial infections worldwide, present in 30-50% of adults in developed countries and 70-90% in some developing regions. Most carriers are asymptomatic, but H. pylori causes about 90% of duodenal ulcers and 70-80% of gastric ulcers, plus contributes to MALT lymphoma and gastric adenocarcinoma risk. Treatment is critical when associated with ulcer disease.

Testing: Stool antigen test, urea breath test, or biopsy during endoscopy. Serology is less useful (does not distinguish current from past infection).

Treatment: Combination antibiotic therapy for 14 days. First-line in regions with low clarithromycin resistance: clarithromycin-based triple therapy (PPI + clarithromycin + amoxicillin or metronidazole). In high-resistance areas: bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole). Compliance is essential — 50-80% eradication with first attempt; second-line therapy if first fails.

After eradication, ulcer healing typically completes within 4-8 weeks of acid suppression. Re-test for cure 4-6 weeks after completing antibiotics, using stool antigen or breath test (not serology).

NSAID-induced ulcer disease

Risk factors for NSAID-related GI bleeding:

• Age over 65
• Prior peptic ulcer disease or GI bleeding
• Concurrent corticosteroid use
• Concurrent anticoagulant or antiplatelet use
• High-dose or chronic NSAID use
• H. pylori infection (multiplies NSAID risk)
• Concurrent SSRI use (modest additional risk)

Prevention strategies: Use acetaminophen when possible. If NSAIDs needed, use lowest dose for shortest duration. For chronic NSAID use in high-risk patients, co-administer PPI or use selective COX-2 inhibitor (celecoxib) which has lower GI risk. Eradicate H. pylori before chronic NSAID use.

Chronic gastritis

Patterns:

• H. pylori gastritis: Most common cause of chronic gastritis worldwide
• Autoimmune gastritis (pernicious anemia): Antibodies against parietal cells lead to atrophic gastritis, B12 deficiency, and increased gastric cancer risk
• Chemical/reactive gastritis: From NSAIDs, alcohol, bile reflux, post-surgical states

Endoscopy with biopsy establishes diagnosis. Treatment: cause-specific. Periodic surveillance endoscopy may be appropriate for atrophic gastritis with intestinal metaplasia or dysplasia given gastric cancer risk.

Cirrhosis-related variceal bleeding

Patients with cirrhosis benefit from variceal screening with endoscopy. If varices identified:

• Small varices: monitoring; consider beta-blocker prophylaxis (propranolol or carvedilol)
• Medium-large varices: beta-blocker prophylaxis or band ligation
• Variceal bleeding history: secondary prophylaxis with band ligation + beta-blocker, eventual TIPS consideration, transplant evaluation

The fundamental approach to known cirrhosis: optimize liver disease management, control portal hypertension, address underlying cause (hepatitis treatment, alcohol abstinence, NASH management), and aggressive variceal surveillance.

Recovery, Follow-Up & Prevention

After a documented bleeding episode

• Complete the prescribed PPI course (typically 4-8 weeks for ulcer healing)
• Complete H. pylori eradication if applicable, with confirmation testing
• Avoid NSAIDs indefinitely or use with strict PPI protection
• Address underlying contributors: alcohol cessation, stress management, smoking cessation
• Repeat endoscopy at 8-12 weeks for gastric ulcers to confirm healing and rule out malignancy (gastric ulcers have higher malignancy concern than duodenal)
• For variceal bleeding survivors: long-term prophylaxis program, liver disease management

Iron deficiency anemia after bleeding

Significant GI bleeding produces iron-deficiency anemia. Replenishment:

• Oral iron (ferrous sulfate 325 mg, ferrous gluconate, or ferrous bisglycinate) once daily or every other day
• Vitamin C with iron for absorption
• Avoid taking with calcium, coffee, tea (impair absorption)
• Expect dark stool while on iron (the GI symptom mimicking, now benign)
• Reassess hemoglobin at 4-6 weeks, ferritin at 2-3 months
• IV iron (Venofer, Injectafer, Feraheme) if oral iron is poorly tolerated or rapid replenishment needed
• Continue iron 3-6 months after hemoglobin normalizes to replenish stores

Long-term prevention

• Use acetaminophen rather than NSAIDs when possible
• If chronic NSAID required: lowest dose, shortest duration, PPI co-therapy in high-risk patients
• H. pylori screen and treat in high-risk populations
• Limit alcohol; avoid binge drinking
• Address GERD with appropriate medical management
• Address chronic stress that may worsen acid-peptic disease
• Routine colorectal cancer screening as age-appropriate
• Continue PPI long-term in patients with prior major bleeding from acid-peptic disease

The Upper GI/Reflux pattern connection

Patients who have recovered from significant upper GI bleeding often have underlying acid-peptic disease that maps to the Upper GI/Reflux primary pattern in the GutIQ system. The pattern protocol includes DGL (deglycyrrhizinated licorice) for mucosal protection, zinc carnosine for healing, melatonin for LES tone, and alginate-based reflux barriers. See the Supplements for Upper GI/Reflux guide for the structured supplement approach as a complement to medical treatment.

The pattern framework is appropriate for ongoing acid-peptic management after acute treatment has resolved the bleeding episode and ulcers have healed. It is not a substitute for emergency or acute care of active bleeding.

Special Populations & Higher-Risk Scenarios

Several patient populations require special consideration when black stool appears.

Older adults (age 65+)

Higher risk for several reasons: greater NSAID exposure for arthritis and pain, more anticoagulant use for cardiac and vascular disease, higher H. pylori prevalence in some cohorts, increased likelihood of vascular malformations (angiodysplasia) in the GI tract, and increased malignancy risk. Lower thresholds for evaluation are appropriate. A 75-year-old with new black stool deserves more aggressive workup than a 25-year-old in the same situation.

Patients on anticoagulants

Warfarin, direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban), antiplatelet agents (clopidogrel, ticagrelor, prasugrel), and aspirin all increase GI bleeding risk substantially. A bleeding source that might produce minor occult bleeding in an unanticoagulated patient produces dramatic melena in an anticoagulated patient. The bleeding source still needs to be identified and treated; the anticoagulation needs to be reversed (sometimes) or managed during the acute episode and then resumed with appropriate protection. Decision-making about resumption involves balancing bleeding risk against thrombotic risk — this is a complex assessment requiring specialist input.

Patients with cirrhosis or chronic liver disease

Variceal bleeding is the major concern. Any black stool or hematemesis in a cirrhotic patient is a medical emergency. Prevention includes endoscopic variceal surveillance, beta-blocker therapy (propranolol or carvedilol) for primary or secondary prophylaxis, eradication of bleeding varices with band ligation, and management of underlying liver disease. The threshold for evaluation is extremely low in cirrhotic patients; they should err strongly toward seeking care for any concerning symptoms.

Pregnant patients

Pregnancy increases reflux and gastroesophageal symptoms (progesterone-mediated LES relaxation, mechanical effects of growing uterus). Most pregnancy-related "dark stool" is iron supplementation related. True melena in pregnancy still requires the same urgency of workup but coordinated with obstetrics. Endoscopy is generally safe in pregnancy if necessary, ideally in second trimester for elective evaluation. Most reflux esophagitis and benign mucosal bleeding in pregnancy responds to PPI therapy (which is generally considered safe). Severe bleeding requires standard evaluation regardless of pregnancy.

Patients post-bariatric surgery

Gastric bypass, sleeve gastrectomy, and other bariatric procedures alter GI anatomy and can predispose to specific bleeding sources: marginal ulcers at the gastrojejunal anastomosis, jejunal ulcers, anastomotic bleeding. Bariatric patients with black stool need evaluation by a bariatric-surgery-aware gastroenterologist. The standard EGD may not visualize all relevant areas of the post-bariatric anatomy; specialized techniques may be required.

Patients with prior GI surgery

Surgical anatomy changes (Whipple procedure, gastrectomy, esophagectomy, intestinal resections) create new vulnerable points for bleeding. Adhesions can cause vascular ectasias. Anastomotic ulcers can develop. Specialist evaluation with the surgical history in mind is important.

Patients on glucocorticoids

Corticosteroids alone do not strongly increase GI bleeding risk, but combined with NSAIDs they multiply risk significantly. The combination of NSAIDs plus systemic corticosteroids is one of the highest-risk medication combinations for upper GI bleeding. PPI prophylaxis is appropriate in patients requiring both medications.

Patients with eating disorders

Severe vomiting (bulimia, hyperemesis) can produce Mallory-Weiss tears or esophagitis. Severe restriction with refeeding can produce gastric hemorrhage. Eating disorder care must be coordinated with GI care.

Pediatric patients

Black stool in children is rare but important. Causes vary by age: in infants, swallowed maternal blood during delivery or breastfeeding (cracked nipples); Meckel's diverticulum (typically presents with painless bleeding); peptic ulcer disease; rarely upper GI malignancy. Pediatric GI evaluation is appropriate; do not extrapolate adult workup pathways without specialist input.

Frequently Asked Questions

Address Your Underlying Gut Pattern

After acute bleeding is resolved and ulcers are healed, the underlying acid-peptic and gut health picture deserves attention to prevent recurrence. The GutIQ pattern system identifies whether your gut configuration matches the Upper GI/Reflux primary pattern and provides a personalized protocol for long-term acid-peptic health.

Medical Disclaimer

This guide is for educational purposes and does not constitute medical advice. Black stool (melena) is a feature of potentially life-threatening upper gastrointestinal bleeding from peptic ulcer disease, esophageal varices, gastric malignancy, vascular malformations, and other conditions. If you have black tarry stool combined with any alarm features (lightheadedness, weakness, rapid heart rate, chest pain, abdominal pain, vomiting blood, recent NSAID or anticoagulant use, known liver disease, history of GI bleeding), seek immediate emergency care. Do not delay evaluation for assumed benign causes when alarm features are present. The home dietary, supplement, and lifestyle interventions in this guide are appropriate for ongoing gut-health maintenance after acute issues have been medically addressed, not substitutes for emergency or acute care. Evidence summaries reflect literature current as of April 2026.